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Background: Kidney disease is an important extra-hepatic manifestation of hepatitis B virus 
(HBV) infection. However, there is paucity of recent literature on kidney disease in children 
and adolescents with HBV infection from several parts of sub-Saharan Africa including 
Nigeria. 
Objective: To review the pattern of kidney disease in hepatitis B surface antigen (HBsAg)-
positive children and adolescents seen at a tertiary hospital in South West Nigeria. 
Methods: A retrospective study was undertaken of HBsAg-seropositive children with kidney 
disease managed at University College Hospital, Ibadan, from January 2004 to December 
2015. Patients were identified from the paediatric nephrology unit admissions and the renal 
histology registers.  
Results: 24 children and adolescents were studied, 17 of whom were male (70.8%), and the 
median age was 10.0 (range 3–15) years. Ten (41.7%) had nephrotic syndrome, five (20.8%) 
had non-nephrotic glomerulonephritis, five (20.8%) were in end-stage renal disease (ESRD), 
including a patient with posterior urethral valves, and four had acute kidney injury secondary 
to acute tubular necrosis. Renal histology was available for ten patients: nine had nephrotic 
syndrome associated with minimal change disease in six, focal segmental glomerulosclerosis 
in two and one had membanoproliferative glomerulonephritis. The patient with non-nephrotic 
glomerulonephritis had diffuse global sclerosis. 
Conclusion: The pattern of kidney disease in HBV-positive children demonstrated a 
predominance of nephrotic syndrome, followed by non-nephrotic glomerulonephritis, ESRD 
and acute kidney injury. Better diagnostic facilities and treatment are required. Prevention of 
HBV infection by universal childhood immunisation is the ultimate goal.  
 
Keywords: Nephrotic syndrome, Glomerulonephritis, End-stage renal disease, HBsAg, 
Hepatitis B-associated nephropathy, Children, Adolescents, Nigeria 
List of abbreviations and their meanings 
AKI: Acute Kidney Injury  
CGN: Chronic glomerulonephritis  
CKD: Chronic kidney disease 
Com: Community 
CRF: Chronic renal failure 
DGS: Diffuse global sclerosis 
ELISA: Enzyme linked immunosorbent assay 
ESRD: End-stage renal disease  
FSGS: Focal segmental glomerulosclerosis 
Hb S: Sickle cell anaemia; 
HBsAg: Hepatitis B surface Antigen 
HBV: Hepatitis B virus 
 IgA: Immunoglobulin A  
KDIGO: Kidney Disease Improving Global Outcomes 
MCD: Minimal change disease 
MPGN: Membranoproliferative glomerulonephritishosp: Hospital  
NA: Not available 
 NS: Nephrotic syndrome 
 PGN: Proliferative glomerulonephritis 
QMN: Quartian malaria nephropathy 
yrs: Years 
Introduction 
Kidney disease is an important extrahepatic manifestation of hepatitis B virus (HBV) 
infection and various forms of glomerular disorders have been described in patients with 
chronic HBV disease. These include membranous nephropathy, membranoproliferative 
glomerulonephritis (MPGN), mesangial proliferative glomerulonephritis, immunoglobulin A 
(IgA) nephropathy, focal segmental glomerulosclerosis (FSGS) and minimal change disease 
(MCD).1,2  The most commonly reported association between HBV and kidney disease in 
children has been with membranous nephropathy.1,2 
The prevalence of HBV-associated glomerulonephritis tends to parallel the prevalence 
of HBV infection. HBV-associated glomerular disease has been reported from regions with 
low, medium and high hepatitis virus endemicity.3–5 However, the greatest number of reports, 
and therefore the sources of greatest detail, are from South-East Asia and South Africa during 
periods of high regional endemicity of HBV infection.2,6–9 The pattern usually observed in 
children is that the disease occurs mainly in males and membranous nephropathy is the most 
common histopathology. Spontaneous regression of nephrotic syndrome, occurs in 30–60% 
of patients with HBV membranous nephropathy and it usually coincides with seroconversion 
of the anti-HBe antigen. The disease, however, runs a benign course in most children and 
only a minority (1.4–2.8%) progress to end-stage renal disease (ESRD). 
It is unclear whether the higher rates of renal disease reported in South Africa and 
South-East Asia compared with other parts of sub-Saharan Africa are because of better access 
to facilities for HBV detection and renal investigations rather than a higher prevalence of 
chronic HBV infection.10,11 Additionally, in highly endemic settings, a decline in HBV 
infection rates and HBV-associated glomerular disease has been recorded following the 
introduction of universal childhood HBV immunisation.2 
Reports on the prevalence of HBV infection in Nigerian children estimate that the rate 
of HBsAg seropositivity in children and adolescents was 6.7–40% before introduction of the 
HBV vaccine into the National Programme on Immunisation in 2004 (Table 1). A recent 
metanalysis of prevalence of HBV infection in Nigeria  noted a pooled prevalence of 11.5% 
in children aged <12 years.12 The current high prevalence may have been associated with 
logistical problems associated with ensuring universal and timely immunisation against HBV 
infection leading to delayed administration of HBV vaccines.13–15 
Management of several forms of kidney disease in many sub-Saharan African 
countries is a challenge because of the poor socio-economic conditions. There is limited 
access to diagnostic facilities, immunosuppressive medication and renal replacement therapy. 
Documentation of positive HBsAg in Nigerian children with kidney disease creates 
additional challenges in terms of the financial burden of laboratory investigations for 
diagnosing and monitoring the HBV infection, and limited facilities for renal histology. In 
addition, financial constraints restrict the choice of and access to antiviral agents. These 
challenges also contribute to limited data on HBV infection and kidney disease in Nigerian 
children (Table 2). 
A description of the clinical spectrum of kidney disease in HBsAg-positive patients is 
an important initial step towards understanding the challenges, designing interventions and 
assessing the outcome of any interventions. This article reviews the clinical and histological 
spectrum of kidney disease in HBsAg-positive children and adolescents attending University 
College Hospital Ibadan (UCH). 
[t]TABLES 1&2[/t] 
 
Methods 
A retrospective analysis of case records of HbsAg-seropositive children and adolescents with 
kidney disease managed by the Paediatric Nephrology Unit, UCH between January 2004 and 
December 2015 (144 months) was undertaken. HBsAg screening is routinely performed in 
patients who are scheduled for haemodialysis and in those with nephrotic syndrome. In 
addition, screening for HBsAg is usually requested in the evaluation of children with diseases 
of the kidney and the urinary tract when the disease is not a congenital anomaly. 
HBsAg-positive patients with kidney disease were identified from the paediatric 
nephrology admissions and renal histology registers. Results of chemical pathology 
investigations and HBsAg were also extracted.  
 
Laboratory investigations 
HBsAg was determined using third-generation ELISA kits at the Department of Medical 
Virology, University of Ibadan. Hepatitis B surface antigen status was determined by rapid 
screening kit in the Department of Haematology, UCH.  
At UCH, renal biopsy is usually undertaken in patients with suspected secondary 
nephrotic syndrome, and in patients with chronic kidney disease (CKD) and non-nephrotic 
glomerulonephritis (provided they are not in end-stage renal disease or do not have shrunken 
kidneys on ultrasound). During the study, renal biopsy was sometimes limited by caregivers’ 
financial constraints. In the earlier stage of the study, the non-availability of renal biopsy 
needles was a barrier. Renal diseases were diagnosed histologically using haematoxylin and 
eosin stain along with three special stains which were periodic acid schiff (PAS), Masson’s 
trichrome and Jones silver stains. Renal biopsies were analysed by light microscopy only. 
Immunofluoresence or electron microscopy was not undertaken on any of the biopsy samples 
as these facilities are not available. In addition, laboratory investigations and treatment in 
many patients were limited by financial constraints as payment is usually out-of-pocket.21  
 
Definitions 
Nephrotic syndrome was defined as massive proteinuria and hypo-albuminaemia with 
hyperlipidaemia.22 Massive proteinuria was defined as 24-hour urinary protein >40 
mg/m2/hour or protein dipstick of ≥3+.22 
Hypertension was defined as blood pressure ≥ 95th percentile for age, gender and 
height.23 Non-nephrotic glomerulonephritis consisted of hypertension, azotaemia and 
proteinuria with or without haematuria. Glomerulonephritis included both nephrotic 
syndrome and non-nephrotic glomerulonephritis.22 Chronic kidney disease (CKD) was staged 
according to the Kidney Disease Improving Global Outcomes (KDIGO) guidelines.24 
In patients with clinical features of septicaemia or haemoglobinuria, acute kidney 
injury (AKI) was attributed to acute tubular necrosis. ESRD was defined as the need for 
dialysis or death from renal failure in patients with clinical features of underlying chronic 
kidney disease.16,24 
 
Statistical analysis 
Categorical data were described using proportions. Non-categorical data were analysed as 
median and range. All analyses were undertaken using the IBM SPSS (International Business 
Machines Statistical package for social sciences) data editor version 21. 
 
Ethics approval 
Ethics approval was granted by the University of Ibadan/University College Hospital Ethics 
Committee. Data were anonymised. 
 
Results 
Patients 
A total of 24 children and adolescents, 17 male (70.8%), with ages ranging from 3 to 15 years 
(median 10.0 years ) were studied. Ten (41.4%) had nephrotic syndrome, five (20.8%) had 
non-nephrotic glomerulonephritis, five (20.8%) were in ESRD, and four (16.7%) had acute 
kidney injury (AKI) secondary to acute tubular necrosis.  
 
Nephrotic syndrome 
The patients with nephrotic syndrome were 3–12 years of age. Eight of the ten were male. 
Renal biopsy results were MCD in five, FSGS in two and MPGN in one. Two of the patients 
with nephrotic syndrome also had CKD stage G3a, and another had CKD stage G2.  
 
Non-nephrotic glomerulonephritis 
Five patients had non-nephrotic glomerulonephritis. Three of the patients with non-nephrotic 
glomerulonephritis had background CKD. Chronic kidney disease was G3a in one of the 
patients and stage 1 in the other two. One of the patients with CKD had diffuse global 
sclerosis on renal biopsy. The two other patients had acute glomerulonephritis, one of whom 
also had clinical features of rapidly progressive glomerulonephritis. 
 
End-stage renal disease 
Five other patients were in ESRD when they were found to be HbsAg-positive. One of them 
had undergone ablation of the posterior urethral valves at the age of 12 years. Another patient 
had nephrotic syndrome and had defaulted from follow-up for approximately 3 years. End-
stage renal disease was secondary to non-nephrotic glomerulonephritis in three patients. 
 
Acute tubular necrosis 
Four patients had AKI secondary to acute tubular necrosis. In two, the acute tubular necrosis 
was secondary to intravascular haemolysis and one other patient had sickle cell anaemia and 
sepsis. 
 
Discussion 
There are few reports on the spectrum of kidney disease in HBsAg-positive Nigerian 
children.(Table 2) In the present study, there were 24 HbsAg-positive children and 
adolescents with renal disease over a 12-year period (2004–2015). The findings in this study 
are in part different from the observations by Ladapo et al. in Lagos as they did not document 
positive serum HBsAg in 108 children with nephrotic syndrome who were seen between 
2008 and 2013.17 The different HBsAg seropositivity in both studies may relate to differences 
in the study period, study population and prevalence of HBsAg positivity in Lagos and Oyo 
States.  
There is heterogeneity in the prevalence of HBsAg in different parts of Nigeria, 
ranging from 0.5 to 46.8 in different parts of the country, as shown in a previous 
metanalysis12 and in Table 1. A recent study from Ibadan showed a low rate of HBsAg 
seropositivity in children attending a secondary health facility;25 however, our study was 
undertaken in a tertiary centre with a potentially higher rate of HBsAg among attendees. 
Differences in access to immunisation, sociocultural practices and prevalence of risk factors 
for vertical and horizontal transmission of HBV infection may account for the differences. 
Additionally, the prevalence of HBV infection varied between different time periods12 with 
an annual decline of 0.8% noted between 2000 and 2013 which might be related to the 
introduction of routine childhood HBV immunisation in 2004. 
In a study published in 1983 before the inclusion of HBV vaccination in the Nigerian 
immunisation schedule, Abdurrahman and colleagues in Northern Nigeria found an HBsAg 
prevalence of 36% in patients with nephrotic syndrome and a higher prevalence of 45.9% in 
controls. However, their renal histology findings demonstrated HBV antigens, 
immunoglobulins and C3 complements in the glomeruli of 12 of 18 patients with nephrotic 
syndrome and positive serum for HBsAg. The finding of HBV antigens in the glomeruli 
support an aetiological role for HBV in at least some of these cases.10  
While the nephrotic syndrome is the most common clinical renal disorder associated 
with HBV infection, patients with non-nephrotic glomerulonephritis and a nephritic/nephrotic 
picture have also been reported.2,10,26 Consistent with previous reports,2,10,26 in this study there 
was a predominance of nephrotic syndrome and non-nephrotic glomerulonephritis in HBsAg-
positive patients with kidney disease.  
Hepatitis B membranous nephropathy usually runs a benign course with only a 
minority progressing to end-stage renal failure.2 In this study, however, a relatively high 
proportion of patients had ESRD. This is consistent with a previous report from Saudi Arabia 
in which four of seven children with HBV-associated membranous nephropathy developed 
ESRD.27 
The role of hepatitis B infection in patients with AKI is not clear. Fulminant hepatitis 
has been associated with AKI, but it was not documented in any of our patients.28 On the 
other hand, non-fulminant HBV infection is a rare cause of acute kidney disease.29 To more 
accurately delineate the role of hepatitis B infection in children with AKI, additional serology 
for hepatitis B antigens and antibodies will be required and renal biopsy undertaken in 
selected patients. 
The study has several limitations. Firstly, HBsAg was the only available seromarker 
of HBV infection, thus limiting characterisation of HBV infection in the patients. Secondly, 
renal biopsy was not undertaken in all patients with glomerulonephritis, and, when renal 
histology was undertaken, it was limited to light microscopy only; facilities for 
immunofluorescence or electron microscopy were not available. The presence of HBsAg 
could not therefore be demonstrated on renal histology, and patients with HBV-related 
nephropathy were not identified. The study, however, provides recent data on the spectrum of 
kidney disease in HBV-positive Nigerian children, and potential areas of support and further 
research. 
Prospective, multi-centre studies are required to further describe the role of HBV 
infection in children in sub-Saharan Africa. Potential areas of support for HBsAg-
seropositive children with kidney disease include access to other viral markers of HBV 
infection such as HBV DNA viral load, and renal histology including immunofluorescence 
and electron microscopy. Antiviral agents should be made available for the treatment of 
affected children. 
To conclude, the spectrum of kidney disease in HBsAg-seropositive children and 
adolescents in Ibadan is described. Patients with HBsAg will require support in the areas of 
access to other markers of HBV infection, renal histology and antiviral therapy. Universal 
immunisation of children to prevent HBV infection and related kidney disease is the ultimate 
goal. 
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Table 1   Studies on the prevalence of HBsAg in Nigerian children (hepatitis B virus vaccine was introduced into the Nigerian Programme on Immunisation in 2004) 
 
 
 
Authors 
 
 
Year 
 
 
Location 
 
Com./hosp.-
based 
 
 
 
Sample size 
 
 
Type of study 
 
 
Age  
 
 
Population 
 
 
Prevalence of HBsAg 
 
Francis et al.30 
 
1971 
 
Ibadan 
 
Com. 
 
423  
 
Cross-sectional 
 
4–20 yrs 
 
School children 
 
6.7% 
Fakunle et al.31 1981 Zaria Hosp. 242 
(61 aged <10 yrs) 
Cross-sectional NA Children and adults  45.9% in children < 10 yrs   
Abdurrahman et 
al.10 
1983 Zaria Hosp. Cases (NS): 50 
Controls:61 
Case-control NA Children 
NS cases and controls 
Cases: 36% 
Controls:45.9% 
Johnson et al.32 1986 Ibadan Hosp. 122 
 
Cross-sectional 6 m–14 yrs Children 15.6% 
Abiodun et al.33 1989 Benin Hosp. Cases (HB S):143 
Controls:161 
Case-control 6 m–12 yrs Children HbS: 39.2% 
Control: 19.3% 
Abiodun et al.34 1991 Benin Hosp. 437 Cross-sectional 2 m–15 yrs Children 10.8% 
Angyo et al.35 1995 Jos Hosp. 501 Cross-sectional 6 m–12 yrs Children 19.5% 
Angyo et al.36  2001 Jos Hosp. Cases (HB S): 507 
Controls: 501 
Case-control   Cases: 22.7% 
Control: 19.6% 
Chukwuka37 2004 Nnewi Com. 
(urban) 
237 Cross-sectional 5-12 yrs Children 7.6% 
Bukbuk38 2005 Maiduguri Com. 
(rural) 
150 Cross-sectional 10–13 yrs Children 44.7% 
Odusanya39 2005 Sabongidda-ora Com. 
(rural) 
Cases (HBV vaccinated): 223 
Controls: 219  
Case-control 1–4 yrs Children Cases: 1.3% 
Controls:4.6% 
Agbede40 2007 Ilorin Hosp. 70 Cross-sectional <1–5 yrs Children 10% 
Alikor et al.41 2007 Portharcourt Hosp. 251 Retrospective study of HBsAg requests ≤16 yrs Children 12.4% 
Onakewhor et al.42 2009 Benin Hosp. 620 Cross-sectional Neonates Neonates 0.96% 
Ugwuja et al 43 2009 Abakaliki Com.. 785 Cross-sectional 12–17 yrs Children 4.1% 
Adoga et al.44 2010 Abuja and 
Nasarawa 
Hosp.-based 1891 
(1056 aged ≤ 20 yrs)  
Cross-sectional ≤10-60 yrs Children and adults 5.1% in patients aged ≤  20 yrs  
Okonko25 2012 Ibadan Hosp.  217  <10–17 yrs Children 0.5% 
David et al.45 2012 Ekiti Com. 1000 Cross-sectional 9–20 yrs Children 11.5% 
Sadoh et al.14 2013 Benin Hosp. 153  1–90 days Children 16.3% 
Sadoh et al.13 2014 Benin Hosp. 150 Cross-sectional 2 m–15 yrs Children 13.8% 
Jibrin et al.46 2014 Sokoto Hosp. Cases (HB S): 300  
Controls: 300 
Case-control 6–15 yrs Children Cases: 17.3% 
Controls:10.7% 
Musa et al.12 2015 NA  NA NA Metanalysis   Children and adults 11.5% in children aged ≤ 12 yrs 
Ikobah et al.47 2016 Calabar Com. 749 Cross-sectional 11–19 yrs Children 1.2% 
Nwokedi et al.48 2010 Kano Hosp. 6395 (adults and children) Retrospective <10–>50 
yrs 
Children and adults 19.5% in patients aged <10 yrs 
Bukbuk et al 49 2016 Maiduguri Com. 836  
(175 aged  <10 yrs) 
 
Cross-sectional 0–56 yrs Children and adults 24.9% in children aged <10 yrs 
 
Com, community; HBsAg, hepatitis B surface antigen; Hb S, sickle cell anaemia; hosp., hospital; NA, not available; NS: Nephrotic syndrome; yrs, years. (Hepatitis B virus 
vaccine was introduced into the Nigerian Programme on Immunisation in 2004). 
 
 
Table 2   Studies of hepatitis B infection and kidney disease in Nigerian children 
 
 
 
 
 
Authors 
 
 
 
 
Year 
 
 
 
 
Location 
 
 
 
Type of 
study 
 
 
 
 
 
Sample size 
 
 
 
HBsAg seropositive 
n (%) 
 
Renal histology in 
HBsAg 
seropositive with 
kidney disease 
 
 
 
 
Other remarks 
 
Abdurrahman 
et al.10 
 
1983 
 
Zaria 
 
Case-control 
 
Cases (NS): 50 
Controls: 61 
 
Cases: 18 (36) 
Controls: 28 (45.9) 
 
MPGN: 9 
QMN: 5 
PGN: 2 
CGN: 1 
Miscellaneous: 1 
 
Histology in cases with HBsAg in kidneys 
MPGN: 8 
PGN: 2 
CGN: 1 
MCD: 1 
Anochie et 
al.19 
2003 Port 
Harcourt 
Case series: 
CRF 
45 2 (4.4) NA The two HBsAg-seropositive children had NS 
Ladapo et 
al.18 
2012 Lagos Case report 1 1 (100) MN Sustained remission of NS following treatment 
with lamivudine  
Asinobi et 
al.16  
2014 Ibadan Case series: 
ESRD 
53 4 (7.5) NA  
Ladapo et 
al.17 
2014 Lagos Case series: 
NS 
108 0 NA  
Asinobi et 
al.20 
2015 Ibadan Case series: 
renal 
histology 
1997–2001: 22 
2006–2013: 56 
1997–2001: 0 
2006–2013: 7 (12.5) 
MCD: 4 
FSGS: 2 
MPGN: 1 
 
     Present 
study 
 
2016 Ibadan Case series 24 24 (100%) MCD:5 
FSGS:2 
MPGN:1 
DGS:1 
 
 
CGN, chronic glomerulonephritis; CRF, chronic renal failure; DGS, Diffuse global sclerosis; ESRD, end-stage renal disease; FSGS, focal segmental glomerulosclerosis; 
HBsAg, hepatitis B surface antigen; MPGN, membranoproliferative glomerulonephritis; MCD, minimal change disease; NS, nephrotic syndrome; QMN, quartian malaria 
nephropathy; PGN, proliferative glomerulonephritis  
